May 29, 2017 (Shareholders Foundation) - An investigation on behalf of investors of Amgen, Inc. (NASDAQ:AMGN) shares over potential securities laws violations by Amgen, Inc. and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Amgen, Inc. (NASDAQ:AMGN) concerning whether a series of statements by Amgen, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Thousand Oaks, CA based Amgen, Inc. is a biotechnology company that discovers, develops, manufactures and delivers various human therapeutics.

Amgen, Inc. reported that its annual Total Revenue rose from over $21.66 billion in 2015 to over $22.99 billion in 2016 and that its Net Income increased from over $6.93 billion in 2015 to over $7.72 billion in 2016.

Shares of Amgen, Inc. (NASDAQ:AMGN) grew from $111.48 per share in May 2014 to as high as $182 per share in March 2017.

On May 21, 2017, Amgen, Inc. announced data from data from active-comparator study of EVENITY (Romosozumab) in postmenopausal women with osteoporosis. Amgen, Inc disclosed that its osteoporosis medicine Evenity raised concerns about heart safety that will lead to a delay in securing approval in the United States. According to data disclosed by Amgen, Inc., a higher percentage of patients who took the drug suffered serious cardiovascular side effects after a year, compared to those who took an older approved medicine.

Shares of Amgen, Inc. (NASDAQ:AMGN) declined on May 23, 2017 to $152.16 per share.

On May 26, 2017, NASDAQ:AMGN shares closed at $155.01 per share.